Лекарственное лечение распространенного рака молочной железа
Диссертация
В последние годы ведутся интенсивные исследования по лекарственной терапии рака молочной железы, основанные на углубленной характеристики болезни. Цитостатическая терапия используется при местно-распространенном и диссеминированном раке молочной железы самостоятельно, в комбинации с гормональной терапией, лучевой терапией и оперативным лечением. Осмысливаются подходы к научно обоснованному… Читать ещё >
Список литературы
- Аксель Е.М., Давыдов М. И. Злокачественные новообразования в России и странах СНГ. Вестник РОНЦ им. Н. Н. Блохина РАМН, Москва, 2002.
- Абашин С.Ю. Роль системной химиотерапии в комбинированном и комплексном лечении больных первичным раком молочной железы. Дис. Докт.мед.наук, Москва, 2000, 289с.
- Богатырев В.Н., Портной Т. Г., Лактионов К. П., Летягин В. П. Проточная цитометрия при раке молочной железы Т1−2МоМо: анализ 10 летних наблюдений. 1 съезд онкологов стран СНГ 1996. Материалы съезда часть 2, с. 482
- Борисов ВИ., Сарибекян Ж Неоадъювантная химиотерапия рака молочной железы. // В сб.: Новое в терапии рака молочной железы / Под ред. Н. И. Переводчиковой. — М.—1998.— С43−47.
- Возный Э. К, Добровольская Н. Ю., Хмелевский Е. В. Лучевое и лукарственное лечение метастазов в кости рака молочной железы // В сб.: Возможности современной лучевой диагностики в медицине. — М. — 1995. — С. 240−241.
- Гарин A.M. Принципы и возможности современной эндокринной терапии опухолей // М.: Просвещение. — 2000. — С. 149.
- Гарин A.M., Хлебнов A.B. Справочник практической химиотерапии опухолей. Москва, 1995, 309с.
- Гарин А. М Сложные ситуации, трудные и спорные вопросы ведения и лечения больных раком молочной железы. // В сб.: Новое в терапии рака молочной железы / Под ред. Н. И. Переводчиковой. — М.—1998 — С67−76.
- Герпггейн Е.С., Кушлинский НЕ.Молекулярные маркеры прогноза и лекарственной чувствительности рака молочной железы. // В сб.: Новое в терапии рака молочной железы / Под ред. H.H. Переводчиковой. — М.—1998.— С19−24.
- Горбунова В.А. Новые цитостатики при раке молочной железы // В сб.: Новое в терапии рака молочной железы / Под ред. Н. И. Переводчиковой. — М—1998.— С. 85−91.
- Грицай A.A. Комбинация химиотерапии и широкопольного облучения при метастазах рака молочной железы в кости //Дисс. канд. мед. наук. — М. — 1987. — 173с.
- Летягин В.П., Шомова М. В., Богатырев В. Н. Лечение местно-распространенного рака молочной железы. //Высокие технологии в онкологии. Материалы V всесороссийского съезда онкологов. Казань, 2000, том. З, с.50−51.
- Летягин В П. Лечение первичного рака молочной железы. // В сб.: Новое в терапии рака молочной железы / Под ред. Н. И. Переводчиковой. — М.—1998.— С32−35.
- Личиницер М.Р. Роль фундаментальных научных исследований в развитии новых методов лечения рака молочной железы. 2-й съезд онкологов стран СНГ с участием ученых Европы, Америки и Азии 05.2000г., Киев, Украина.
- Личиницер М.Р. Бондронат новые возможности в терапиикостных метастазов рака молочной железы. 5 ежегодная Российская онкологическая конференция, Москва, 2001.
- Любимова Н.В. Биохимические маркеры костного ремоделирования при поражении скелета у онкологических больных./ Автореферат докт. Дис., Москва, 1999, 56с.
- Модников О.П., Новиков Г. А., Родионов В. В. костные метастазы рака молочной железы. (Патогенез, клиника, диагностика и лечение). Москва, 2001.-255с.
- Моисеенко В.М., Семиглазов В. Ф., Тюляндин С. А. Современное лекарственное лечение местнораспространенного и метастатического рака молочной железы. — //СПб.: Грифон, 1997. 204 с.
- Навельбин (винорельбин) в химиотерапии злокачественных опухолей. /Под редакцией В. А. Горбуновой, Москва, 1998, 40с.
- Николаева Т.П., Добрынин Я. В., Басов Б. Н. и др. Проточная ДНК-цитометрия в прогнозировании течения рака молочной железы. //Вестник ОНЦ РАМН, 1994, N1, с. 30−37.
- Новые цитостатики в терапии злокачественных опухолей / Под ред. В. А. Горбуновой. М., 1998. — С. 216.
- Огнерубов H.A., Летягин В. П., Поддубная И. В. Неоадъювантная химиолучевая терапия в комплексном лечении местнораспространенного рака молочной железы. //Изд-во Воронежского университета. Воронеж, 1993, 71с.
- Опухоли молочной железы (клиника, диагностика, лечение, прогноз)./ Под редакцией проф. В. П. Летягина, Москва, 2000, 395с.
- Переводчикова Н.И. Новое в терапии рака молочной железы1. Москва, 1998 -98стр.
- Переводчикова Н.И. Терапия метастатических (диссеминированных) форм рака молочной железы // В сб.: Новое в терапии рака молочной железы / Под ред. Н. И. Переводчиковой. — М.—1998.—С53−67.
- Поддубная И.В. Достижения современной химиотерапии. //Современная онкология. Москва, 2003. № 2, том 5, с. 49.
- Стандарты лечения больных первичным раком молочной железы. /Под ред. Давыдова М. И., Летягина В. П. РОНЦ им. Н. Н. Блохина РАМН, Москва, 2003, 40с.
- Стенина М. Б .Новые противоопухолевые препараты в лечении местнораспространенного и метастатического рака молочной железы. /Дис. Д.м.н. Москва, 2002, 281с.
- Ткачев С.И., Гладилина И. А., Алиева С. Б. Отдаленные результаты консервативного лечения неоперабельного рака молочной железы. Возможности современной онкологии в диагностике и лечении злокачественных заболеваний. //Москва, 2003, с.154−158.
- Шомова М.В. Местнораспространенный рак молочной железы (лечение и факторы прогноза). /Дис.докт.мед.наук. Москва, 1999, 216с.
- A’Hern R.P., Smith I.E., Ebbs S.R. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. //Br J Cancer 1993−67:801−805.
- Alonso V, Santader C, Florian J, Alonso M, Isla MD, Escudero P, Saenz A, Tres A. Phase II trial of oral tegafur and folinic acid with mitoxantrone as first-line regimen in patients with metastatic breast cancer. //Tumori 1996 Jan-Feb-82(l):61−4
- Amadori D., Silvestrini R. Prognostic and predictive value of thymidine labelling index in breast cancer Breast Cancer Research and Treatment Kluwer Boston, //USA CONTENTS VOL. 51, NO. 3, 1998, 267−281
- Antoine E.C., Meric J.B., Coeffic D. et al. Anthracycline-primary resistant breast cancer (APRBC): confirmatory results of the high level of activity of the do-cetaxel (D)-cisplatin © regimen. //Proc. Am. Soc. Clin Oncol 1999- 18:491a.
- Ardavanis A., Extra J.M., Espie M., Cuvier C., Marty M. Phase II trial of a combi-nation of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer. //In Vivo 1998 Sep-Oct-12(5):559−62.
- Arguello F, Baggs RB, Frantz CN. A murine model of exper imental metastasis to bone and bone marrow. IICancer Res 1988−48:6876−6881.
- Blackstein M., Vogel C.L., Ambinder R. et al. Phase II study of gemcitabine in patients with metastatic breast cancer. //Eur. J. Cancer 1997- 33(suppl 8) :S149a.
- Blum JL et al. A multicenter phase II trial of Xeloda in taxane-refractory metastatic breast cancer. //Cancer 2001−92:1759−68
- Blum JL et al. Capecitabine (Xeloda) in 162 patients with paclitaxel-pretreated mbc: updated results and analysis of dose modification. //J. Clin. Oncol. 1999- 17:485
- Boxer DI, Todd CE, Coleman R, Fogelman I. Bone secondaries in breast cancer: the solitary metastasis. //J. Nucl. Med. 1989- 30: 13 181 320.
- Brower ST, Tartter PI, Ahmed S, et al: Proliferative indices and oncoprotein expression in benign and malignant breast biopsies. //Ann. Surg. Oncol. 2:416−423, 1995
- Bruno S, Puerto VL, Mickiewicz E et al. Phase II trial of weekly i.v. vinorel-bine as a single agent in first-line advanced breast cancer chemotherapy: the Latin-American experience. //Am J Clin Oncol 1995 — 18 :392 -396.
- Bull JM, Tormey DC, Li SH et al. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. //Cancer 1978−41:1649−1657.
- Camplejohn RS, Ash CM, Gillett CE, et al: The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre. //Br J Cancer 71:140−145, 1995
- Canobbio L, Boccardo F, Pastorino G et al. Phase-II study of Navelbine® in advanced breast cancer. //Semin Oncol 1989 — 16(suppl 4) :33 -36.
- Cardoso F., A. Di Leo, C. Lohrisch, C. Bernard, F. Ferreira & M. J. Piccart Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? //Annals of Oncology 13: №-207.2002
- Carmichael J, Possinger K, Phillip P et al. Advanced breast cancer: a phase II trial with gemcitabine. //J. Clin. Oncol. 1995 — 13 :2731 -2736.
- Cartazar P., Johnson B.E. Review of the efficacy of Individualized Chemotherapy Selected by in Vitro drug sensitivity testing for patients with cancer///J.of Clin.Oncol. Vol. 17, N5, 1999, P.1625−1631
- Cecchini, MG, Ball R, Gautschi E, Miescher S, Wetterwald A, Zimmermann R, Stadler B. Identification of a bone marrow endothelium homing peptide by phage peptide library pan ning in vivo J Bone Miner Res Suppl 1,1997- S. 115.
- Chan S, Friedrichs K, Noel D et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. //J. Clin. Oncol. 1999−17:2341−2354.
- Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. //Br. J. Cancer 1998- 77:336−340.
- Colemnn RE, Rubens RD. The clinical course of bone metastases from breast cancer. //Br. J. Cancer 1987- 55: 61−66.
- Cook AM, Chambers EJ, Rees GJ. Comparison of mitozantrone and epirubicin in advanced breast cancer. //Clin Oncol (R Coll Radiol) 1996−8(6):363−6
- Cook DL, Weaver DL: Comparison of DNA content, S-phase fraction, and survival between medullary and ductal carcinoma of the breast. //Am. J. Clin. Pathol. 104:17−22, 1995
- Cooke TG, Stanton PD, Winstanley J, Murray GD, Croton R, Holt S, George WD: Long term prognostic significance of thymidine labeling index in primary breast cancer. //Eur. J. Cancer 28:424−426, 1992
- Cortes J.E., Pazdur R. Docetaxel. //J. Clin. Oncol. 1995- 13:2643−2655.
- Dean P.M. Methods of data analysis in flow cytometry. //Academic. Press Inc., London 1985 pp. 195−225.
- Depierre A., Freyer G., Jassem J., Orfeuvre H., Ramlau R, Lemarie E, Koralewski P, Mauriac L, Breton JL, Delozier T, Trillet-Lenoir V. Oral vinorelbine: feasibil- ity and safety profile. //Ann. Oncol. 2001 Dec- 12(12): 1677−81
- DeVita, Helman S., Rosenberg A. Cancer Principles and practice of oncology. //USA, Philadelphia, VI pub. 2001.
- Diel IJ, Solomayer EF, Costa SD et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. //N. Engl. J. Med. 1998- 339:357−363.
- Elledge RM, Clark CM, Hon J/ Rapid in vitro assay for predicting response to fluorouracil in patients with metastatic breast cancer.// J Clin Oncol 1995. 17: 419−423,
- Estaban E et al. Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer. //Breast Cancer Res. Treat. 1999, Nov-.58(2): 141−50
- Esteva FJ, Hortobagyi GN. Adjuvant systemic therapy for primary breast cancer. //Surg. Clin. North. Am. 1999-.79:1075−1090
- Ferno M, Baldetorp B, Bendahl P-O, et al: Recurrence-free survival in Dreast cancer improved by adjuvant tamoxifen — especially forprogesterone receptor positive tumors with a high proliferation. //Breast Cancer Res. Treat. 36:23−34, 1995
- Ferrero JM, Pivot X, Namer M, Wendling JL, Frenay M, Francois E, Hoch M, Teissier E. Combination of mitoxantrone-vinorelbine as firstline chemotherapy for metastatic breast carcinoma //Bull. Cancer 1995 Mar-82(3):202−7
- Foley J. Wysolmerski J. J. Parathyroid hormone-related protein gene expression in human squamous carcinoma cells is repressed by mutant isoforrnsofp53. //Cancer research. 56/17 (4056−4062) 1996.
- Fornasiero A et al. Neoadjuvant moderately high-dose chemotherapy with rh-G-CSF in locally advanced breast carcinoma. //Tumori, 2001 Jul-Aug-87(4):223−8.
- Fossati R, Confalonieri C, Torri V et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials in-volving 31,510 women. //J. Clin. Oncol. 1998- 16:3439−3460.
- French Epirubicin Study Group. A prospective randomized phase III trial com-paring combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. //J. Clin. Oncol. 1988- 6:679−688
- French Epirubicin Study Group. A prospective randomized trial comparing fluorouracil, cyclophosphamide, and epirubicin regimensdiffering in epirubicin dose in advanced breast cancer patients. //J. Clin. Oncol. 1996- 7:295−304.
- Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, Imadalou K, Trillet-Lenoir V. Phase II study of oral vinorelbine in firstline advanced breast cancer chemotherapy. //J. Clin. Oncol. 2003 Jan l-21(l):35−40.
- Fried J. Method for the quantitative evaluation of the data from flow microfluorometry. //Comt. Biomed Res., 1976, v.9, p. 263
- Fumoleau P et al. Capecitabine (XELODA) in patients with advanced breast cancer (ABC), previously treated with antracyclines and taxanes: results of a large phase II study. //Proc. Am.Soc. Clin. Oncol. 2002−20:62a (Abst 247).
- Fumoleau P, Delgado FM, Delozier T et al. Phase II trial of weekly intravenous vinorelbine as first-line advanced breast cancer chemotherapy. //J. Clin. Oncol. 1993 — 11 :1245−1252.
- G. van der Pluijm, C. Lowik and S. Papapoulos Tumour progression and angiogenesis in bone metastasis from breast cancer: new approaches to an old problem. // Cancer treatment reviews, 2000, Volume 26 Number 1 February p. 11−29
- Gainford C, O’Leaiy M, El-Fiki T et al. Phase I trial of docetaxel (T) and cis- platin (P) as first-line chemotherapy for metastatic breast cancer (MBC). //Proc. Am. Soc.Clin. Oncol. 2000- 19:439a.
- Galasko CSB. The anatomy and pathways of skeletal metastases. In Weiss L, Gilbert AH (eds): Bone Metastases. //Boston, MA: G. K. Hall 1981−49−63.
- Garcia-Conde J, Lluch A, Martin M et al. Phase II trial of weekly IV vinorel-bine in first-line advanced breast cancer chemotherapy. //Ann. Oncol. 1994 — 5 :854−857.
- Gelmon KA, O’Reilly SE, Tolcher AW et al. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. //J. Clin. Oncol. 1996−14:1185−1191
- Gladieff L, Houyau P, Mihura J, Martinez M, Caunes N, Chevreau C, Bugat R, Roche H. A phase II study with mitoxantrone-vinorelbine association in the treatment of advanced breast cancer in elderly women. //Bull Cancer 1996 Sep-83(9):703−6
- Gralow JR, Ellis JK, Williams MA et al. Study of docetaxel plus vinorelbine. //Proc. Am. Soc. Clin. Oncol. 2000- 19:106a.
- Greenlee RT, Hill-Harmon MB, Murray T et al. Cancer Statistics, 2001. HC. A. Cancer J. Clin. 2001−51:15−36
- Gregory R. Mundy Metastasis to bone: causes, consequences and therapeutic opportunities. // 2002 Nature Publishing Group SI4 j AUGUST 2002 | VOLUME 2
- Guise TA, Mundy GR. Cancer and Bone. /Endocrine Reviews 1998- 19:18−54.
- Heinemann V. Gemcitabine plus cisplatin for the treatment of metastatic breast cancer. //Clin Breast Cancer 2002 May-3 Suppl 1:24−9
- Henderson 1C. Chemotherapy for metastatic disease. In: Harris JR, Hellman S, Henderson C. et al., eds. Breast Diseases. //Philadelphia: J.B. Lippincott Company, 1991:604−665
- Hery M, Gioanni J, Lalanne CM, Namer M, Coudri A: The DNA labeling index: a prognostic factor in node-negative breast cancer. //Breast Cancer Res Treat 9:207−212, 1987
- Hietanen P, Blomqvist C, Wasenius V-M, et al: Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? //Br J Cancer 71:1029−1032, 1995
- Hngels K, Fox SB, Harris AL. Angiogenesis as a biologic and prognostic indicator in human breast carcinoma. In Goldberg ID & Rosen EM (eds) IIRegulation of Angiogenesis, Birkhauser Verlag/Basel, Switzerland, 1997: 113−156.
- Hortobagyi GN. Treatment of breast cancer. //N Engl J Med 1998−339: 974−984
- Hryniuk WM, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. //J Clin Oncol 1984−2:1281−1288
- Jensen B. V., T. Skovsgaard, S. L. Nielsen. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients //Annals of Oncology 13:699−709,2002
- Jensen B.V., T. Skovsgaard et al. Monitoring of anthracycline cardiotoxicity and future perspectives. //Annals of Oncology 2202, v. 11:451−460.
- Joensuu H, Holli K, Heikkinen M et al. Combination chemotherapyversus sin-gle-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. //J. Clin. Oncol 1998−16:3720−3730
- Joensuu H, Holli K, Heikkinen M. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. //J Clin Oncol 1998- 16: 3720−3730
- Kardinal CG, Cole JT. Chemotherapy of breast cancer. In: Perry MC, ed. The Chemotherapy Source Book (Second Edition). //Baltimore: Williams and Willkins, 1997:1139−1183.
- Kern DH, Weisenthal LM: Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. //J Nail Cancer Inst 82: 582−588, 1990
- Koizumi M., M. Yoshimoto, F. Kasumi & E. Ogata Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients//Annals of Oncology 14: 1234−1240.2003
- Konig E, Kurbacher C, Schwonzen M, Breidenbach M, Mallmann P. A phase II study of dose-dense docetaxel and mitoxantrone in the treatment of patients with high-risk metastatic breast cancer. //Anticancer Drugs 2002 Sep-13(8):827−32
- Kostenuik PJ, Singh G, Suyama KL, Orr FW. Stimulation of bone resorption results in a selective increase in growth rate of spontaneously metastatic Walker 256 cancer cells in bone. IIClin Exp Metastasis 1992- 10:411−418.
- Krasnow AZ, Hellman RS, Timins ME et al. Diagnostic bone scanning in oncology. //Semin Nucl Med 1997- 27: 107−141.
- Kurebayaslii J. Sonoo H. Parathyroid hormone-related protein secretion is inhibited by oestradiol and stimulated by KPL-3C human breast cancer cells. British journal of cancer 75/12 (1819−1825) 1997.
- Kurebayaslii J. Kurosumi M. A new human breast cancer cell line, KPL-3C, secretes parathyroid hormone-related protein and prodused tumours assotiated with microcalcifications in nude mice. British journal of cancer 74/2 (200−207) 1996.
- Kute TE, Quadri Y, Muss H, et al: Flow cytometry in node-positive breast cancer: Cancer and Leukemia Group B protocol 8869. Cytometry 22:297−306, 1995
- Kwai AH, Stomper PC, Kaplan WD. Clinical significance of isolated scintigraphic sternal lesions in patients with breast cancer. //J Nucl Med 1988- 29: 324−328.
- Lochter A, Bissell MJ. Involvement of extracellular matrix constituents in breast cancer. USem in Cancer Biol 1995- 6: 165−173.
- Mammoliti S, Merlini L, Caroti C, Gallo L. Phase II study of mitoxantrone, 5-fluorouracil, and levo-leucovorin (MLF) in elderly advanced breast cancer pa-tients. //Breast Cancer Res Treat 1996−37(l):93−6
- Manishen WJ, Sivananthan K, Orr FW. Resorbing bone stim ulates tumor cell growth. A role for the host microenvironment in bone metastasis. IIAm J Pathol 1986- 123: 39−45.
- McEwan AJB. Unsealed source therapy of painful none metastases: an update. //Semin Nucl Med 1997- 27: 165−182.
- Meyer JS, Friedman E, McCrote MM, Bauer WC: Prediction of early course of breast carcinoma by thymidine labeling. //Cancer 51:18 791 886, 1983
- Meyer JS, Province M: Proliferative index of breast cancer by thymidine labeling index: prognostic power independent of stage, estrogen and progesterone recep-tors. //Breast Cancer Res Treat 12:191 203, 1988
- Miwa M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5- fluoruracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. //Eur J Cancer 1998−34:1274−81
- Muhonen T, Jantunen I, Pertovaara H, Voutilainen L, Maiche A,
- Blomqvist C, Pyrhonen S, Kellokumpu-Lehtinen P. Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. //Am J Clin Oncol 1996 Jun-19(3):232−4
- Mundy J. R. Mechanism of bone metastases //Cancer. 80/8 (suppl) (1546−1556) 1997.
- Muss HB, White DR, Richards F et al. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. Cancer 1978−42:2142−2148.
- Mustacchi G., M. Muggia, S. Milani, R. Ceccherini, M. L. Leita and C. Del-lach. A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer. //Annals of Oncology 13:1730−1736, 2002
- Nabholtz J-M, Falkson G, Campos D et al. A phase III trial comparing doxoru-bicin and docetaxel (AT) to doxoubicin and cyclophosphamide (AC) as first line therapy for MBC. //Proc Am Soc Clin Oncol 1999−18:127a.
- Namer M et al. Results of a phase III prospective, randomized trial, comparing mitoxantrone and vinorelbine in combination with standart FAC/FEC in front line therapy of metastatic breast cancer. //Eur J Cancer 2001 Jun-37(9):l 132−40.
- Nielsen D, Dombernowsky P, Larsen SK, Hansen OP, Skovsgaard T. Epirubi-cin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study. //Cancer Chemother Pharmacol 2000−46(6):459−66
- Orr FW, Milar-Book W, Singh G. Chemotactic activity of bone and platelet TGFp for bone metastasizing rat Walker carci nosarcoma cells. //Invasion Metastasis 1990- 10: 241−252 (1990).
- Orr FW, Sanchez-Sweatman OH, Kostenuik P, Singh G. Tumor-bone interactions in skeletal metastasis. I/Clin Ortop RelRes 1995−312:19−33.
- Orr FW, Varani J, Gondek MD, Ward PA, Mundy GR. Chemotactic responses of -tumor cells to products of resorbing bone.// Science 1979- 203: 176−179.
- O’Shaughnessy J et al. A randomized phase II study of Xeloda vs CMF as first-line chemotherapy of breast cancer in woman aged > 55 years. //Proc Am Soc Clin Oncol 1998−17:103a (Abs 398)
- O’Shaughnessy J et al. //J Clin Oncol 2002−20(12):2812−23
- Ottesen GL, Christensen IJ, Larsen JK, et al: DNA aneuploidy in early breast cancer. //Br J Cancer 72: 832−839, 1995
- Paradiso A, Mangia A, Picciarello M: Fattori prog-nostici nel carcinoma della mammella operabile N~: attivita proliferativa e caratteristiche clinico-patolo-giche. //Folia Oncol 3:1−13, 1992
- Pawlicki M., J. Rolski, J. Zaluski, P. Siedlecki, C. Ramlau, P. Tomzak A Phase II Study of Intravenous Navelbine and Doxorubicin Combination in Previously Untreated Advanced Breast Carcinoma //The Oncologist, Vol. 7, No. 3, 205−209, June 2002
- Pescia V, Bordenave HR, Foglia S et al. Taxotere (T) and cisplatin (P) in an-thracycline-pretreated advanced breast cancer (ABC): preliminary results. //Proc Am Soc Clin Oncol 2000- 19:452a.
- Pinto A.E., Andre S, Noguira M. et al. Flow cytometric DNA hypertetraploidy is associated with unfavorable prognostic features in breast cancer //J.Clin Pathol 1997, 50(7), p 591−595
- Possinger K, Kaufmann M, Heising M et al. Advanced breast cancer: a phase II trial with gemcitabine (gem).// Eur J Cancer 1995 — 3 l (suppl 5) :S80a.
- Pyke C. M. Menezes G. Is parathyroid hormone-related protein a sensitive marker in advanced breast cancer? //Australian and New Zealand journal of surgery.67/5 (256−259) 1997
- R Silvestrini et al: Quality control for the evaluation of the S-phase fraction by flow cytometry: a multi-centric study. //Cytometry (Communications in Clinical Cytometry) 18:11−16, 1994
- Rubens R.D. Bone metastases—the clinical problem. //European Journal of Cancer Volume 34 Number 2 1998 210−214
- R.E. Coleman Monitoring of bone metastases European //Journal of
- Cancer Volume 34 Number 2 1998 252−260
- Ranson MR, Carmichael J, O’Byrne K et al. Treatment of advanced breast can-cer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. //J Clin Oncol 1997- 15:3185−3191
- Reichardt P et al. Capecitabine: The new standard in metastatic breast cancer failing anthracycline and taxane-containing chemotherapy? Mature results of a large multicenter phase II trial. //Eur J Cancer 2001−37(Suppl. 6):S191 (Abst 699)
- Resnick D, Niwayama G. Skeletal metastases. In Resnick D (ed): Diagnosis of Bone and Joint Disorders, 3rd edition. Philadelphia, PA: //Saunders 1995- 3991A064.
- Rita S. Mehta, Richard Bornstein, Ing-Ru Yu. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. // Breast Cancer Research and Treatment 2001,.66: 225−237.
- Romero H., Scheider J., Burgos J et al. S-phase fraction identifies high-risk subgroups among DNA- diploid breast cancer Breast Cancer Res Treat 1996, 38 (3), p 265−275
- Sakamoto G. Infiltrating carcinoma: major histological types. In Page DL, Anderson TJ (eds): Diagnostic Histopathology of the //Breast. London, UK: Churchill Livingstone 1987- 193−235.
- Sanchez-Rovira P, Jaen A, Gonzalez E, Porras I, Duenas R, Medina B,
- Mohedano N, Fernandez M, Martos M, Lozano A, Carrasco E. Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in me-tastatic breast cancer. Final results from a phase II trial. //Oncology (Huntingt) 2001 Feb- 15(2 Suppl 3):44−7
- Sasaki A, Alcalde RE, Nishiyama A, Lim DD, Mese H, Akedo H, Matsumura T. Angiogenesis inhibitor TNP-470 inhibits human breast cancer Osteolytic bone metastasis in nude mice through the reduction of bone resorption. ??Cancer Res 1998- 58: 462A67.
- Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. IICancer Res 1995- 55: 3551−3557.
- Schuller J et al. Preferential activation of Capecitabine in tumor following oral administration in colorectal cancer patients. //Cancer Chemother Pharmacol 2000
- Semenov N., Stepanova E. Expression of PTHR in breast cancer patients with bone metastases. //Journal of Bone Mineral Metabolism, Japan, 2001, Volume 19 p.157−159
- Shapiro CL, Ervin T, Welles L et al. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 //Study Group. J Clin Oncol 1999- 17:1435−1441
- Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Metastatic breast cancer confined to skeletal system. An indolent disease. //Am J Med 1986- 81:381−386.
- Silvestrini R, Daidone MG, Gasparini G: Cell kinetics as aprognostic marker in node-negative breast cancer. //Cancer 56:19 821 987, 1985
- Silvestrini R, Daidone MG, Di Fronzo G, Morabito A, Valagussa P, Bonadonna G: Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. //Breast Cancer Res Treat 7:161−169, 1986
- Silvestrini R, Daidone MG, Luisi A, Boracchi P, Mezzetti M, Di Fronzo G, Andreola S, Veronesi U: Biologic and clinico-pathologic factors as indicators of specific relapse types in node-negative breast cancer. //J Clin Oncol 13:697−704, 1995
- Silvestrini R, Daidone MG, Valagussa P, Di Fronzo G, Mezzanotte G, Bonadonna G: Cell kinetics as a prognostic indicator in node-negative breast cancer. //Eur J Cancer Clin Oncol 25:1165−1171, 1989
- Silvestrini R, Valentinis B, Daidone MG, Di Fronzo G, Coradini D, Salvadori B: Biological characteri-zation of primary and metachronous lesions in breast cancer patients. //Eur J Cancer 28A:2006−2010, 1992
- Sledge GW, Neuberg D, Ingle J et al. Phase III trial of doxorubicin (A) vs. pa-clitaxel (P) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. //J Clin Oncol 2002
- Sobin LH, Witterkind CH (eds). International Union Against Cancer. TNM Classification of Malignant Tumours, 5th edition (Japaneseedition). //Tokyo, Japan: Kinbara 1997.
- Spielmann M, Kalla S, Llombart-Cussac A et al. Activity of gemcitabine in me-tastatic breast cancer (MBC) patients previously treated with anthracyclinecontaining regimens. //Eur J Cancer 1997 — 33(suppl 8) :S149a.
- Spielmann M, Llombart A, Zelek L et al. Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer. //Ann Oncol 1999−10:1457−1460
- Stadtmauer EA, Goldstein LJ, Glick JH. High-dose chemotherapy plus hematopoietic stem-cell rescue for metastatic breast cancer—reply. N Engl J Med2000−343:440−441
- Stal 0, Skoog L, Rutqvist LE, et al: S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. //Br J Cancer 70:1258−1262, 1994
- Stal O, Sullivan S, Sun X-F, et al: Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry. //Cytometiy 16: 160−168, 1994
- Swain SM, Whaley FS, Gerber MC, et al: Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. //J Clin Oncol 15: 1333−1340, 1997
- T. Hiraga, S. Tanaka, M. Ikegame, M. Koizumi, H. Iguchi, T. Nakajima and H. Ozawa Morphology of bone metastasis. //European Journal of Cancer Volume 34 Number 2 1998 230−240
- Talbot D et al. Br J Cancer 2002−86:1367−72
- Tanaka R. Okada M. In vivo antagonistic activiti of a novel RPHrPanalogue against parathyroid hormone-related protein. //Biomedical research (Japan) 17/5 (379−384) 1996.
- The Japanese Breast Cancer Society. General Rules for Clinical and Pathological Recording of Breast Cancer, 13th edition. //Tokyo, Japan: Kinbara 1998.
- Therasse P, Cortazar P, Johnson BE: Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. //J Clin Oncol 17: 1125−1631, 1999 multicenter study. J Clin Oncol 2003- In press.
- Thierry P. Et al. Chemotherapy Response of Breast Cancer Depends on HER-2 Status and Anthracycline Dose Intensity in the Neoadjuvant //Setting Clinical Can-cer Research Vol. 7, 1577−1581, June 2001
- Tormey DC, Weinberg VE, Leone LA et al. A comparison of intermittent vs. continuous use of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer: a Cancer and Leukemia Group B Study. Am J Clin Oncol (CCT) 1984−7:231−239.
- Tubiana M, Pejovic MH, Chavaudra N, Contesso G, Malaise EP: The long term prognostic significance of the thymidine labeling index in breast cancer. Int J Cancer 33:441−445, 1984
- Tubiana M, Pejovic MH, Koscielny S, Chavaudra N, Malaise E:
- Growth rate, kinetics of tumor cell pro-liferation, and long term outcome in human breast cancer. // Int J Cancer 44:17−22, 1987
- Tubiana-Hulin M. Incidence, prevalence and distribution of bone metastasis.// Bone 1991- 12(Suppl 1):9~10.
- Twelves CJ, Dobbs NA, Curnow A et al. A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. //Br J Cancer 1994 — 70 :990 -993.
- V. Grill, W. Rankin and T.J. Martin Parathyroid hormone-related protein (PTHrP) and hypercalcaemia //European Journal of Cancer 222 230
- Valero V. Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. //Semin Oncol 1997−24:S13−1-S13−18.
- Wasserheit C, Frazein A, Oratz R et al. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotox-icity. //J Clin Oncol 1996−14:1993−1999
- Welt A et al. Capecitabine in combination with vinorelbin in pretreated patients with metastatic breast cancer Results of an extended phase IIstudy Ann Oncol 2002- 56 (Abst 202)
- Wenger CR, GM Clark J S-phase fraction and breast cancer — a decade of experience. Breast Cancer Research and Treatment //Kluwer Boston, USA CONTENTS VOL. 51, NO. 3, 1998, 255−265
- Wingren S, Stal O, Sullivan S, et al: S-phase fraction after gating on epithelial cells predicts recurrence in node-negative breast cancer. // Int J Cancer 59:7−10, 1994
- Yoneda T, Sasaki A, Mundy GR. Osteolytic bone disease in breast cancer. I? Breast Cancer Res Treat 1994- 32: 73−84.